Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...
Khan Academy’s AI Pilot Program.
Learn About the Launch of Khan Academy's AI Pilot Program on Bloomberg Radio.
Sal...
Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.
Adding to 2023 Biotech Stock Review Watch List. We Think This One Has Legs.
Starting Due Diligence...
Report: Expedia, Doordash, eCommerce Fashion Retailer and YouTube All Rolled Into One?
Society Pass (SOPA) has Acquired and is Operating in Six Verticals, With More to Come.
Society Pass currently has...
Is Smart for Life (SMFL) $4.30, a Bargain Post Reverse Split?
We Think Yes..!
With the year just finished ringing in $17.8 million in revenues, versus a market capitalization of...
Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?
After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in...
The Ketamine Endgame. Silo Pharmaceutical (SILO).
James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...
The Ketamine Cure (NY Times)
The once-taboo drug has been repurposed to treat depression and is even available for delivery. But how safe is it?
A Good Bear Market, is a Terrible Thing to Waste. How to Short Real...
"The commercial real estate market is tumbling toward a crash that could be as devastating as the 2008-09 crisis. The party’s over,...